All In Biotech

Drug Trial Radar · NCT06671054

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy and Safety of Oral AP1189 Administered at the Doses of 40, 70, or 100 mg for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Participants With Early Rheumatoid Arthritis and Active Inflammation.

Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
SynAct Pharma ApsIndustry
Sponsor type
Industry
Collaborators
NBCD A/S
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

  • AP1189, 40 mgDrug

    AP1189 tablets for oral use

  • AP1189, 70 mgDrug

    AP1189 tablets for oral use

  • AP1189, 100 mgDrug

    AP1189 tablets for oral use

  • AP1189 matching placeboDrug

    AP1189 tablets for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Disease Activity Score 28 (DAS28)-C-Reactive Protein (CRP)Time frame: Week 12

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • Nouvelle Clinical Research LLC

    Cutler Bay, Florida · Recruiting

  • Millennium Medical Research LLC

    Miami, Florida · Recruiting

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania · Recruiting

  • Diagnostic Consultative Center Aleksandrovska

    Sofia, Bulgaria · Recruiting

  • Medical Center Tera Medico

    Vratsa, Bulgaria · Recruiting

  • Sanos Clinic Herlev

    Herlev, Denmark · Recruiting

  • IMSP Spitalul Clinic Municipal "Sfanta Treime"

    Chisinau, Moldova · Recruiting

  • M2Mmed

    Chorzów, Poland · Recruiting

  • Vita Longa Sp. z o. o.

    Katowice, Poland · Recruiting

  • Medyczne Centrum Hetmańska

    Poznan, Poland · Recruiting

  • DC-MED Michal Kowalski S.K.

    Swidnica, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.